GO is a recombinant mAb targeting the CD33 antigen, conjugated via a cleavable linker to a cytotoxic antibiotic derivative of calicheamicin [13]. In May 2000, the FDA granted accelerated approval to GO for patients with CD33-positive relapsed AML who were not suitable for conventional chemotherapy [13, 14]. However, the phase III trial SWOG S0106 found no statistically significant difference in outcomes from the addition of GO to chemotherapy [daunorubicin and cytarabine (DA)] compared to chemotherapy alone, with a higher mortality rate in the combination arm. Based on these results, in June 2010, Pfizer voluntarily withdrew GO from the market [15]. Nonetheless, GO was further evaluated with DA using alternative fractionated dosing schedules in the phase III ALFA-0701 trial and as monotherapy in the phase II AML-19 trial [16, 17]. Administration of lower fractionated doses of GO in combination with chemotherapy in the ALFA-0701 trials resulted in significant improvements in event-free survival (EFS) and OS, although with a higher frequency of grade 3 (G3) or higher adverse events (AEs) in the GO group (predominantly infections and skin toxicities) [16]. Based on these results, GO was re-approved by the FDA in 2017 with DA or as a monotherapy for the treatment of patients with CD33-positive newly-diagnosed AML. In June 2020 the approval was extended to the pediatric population based on the results of the AAML0531 trial, which demonstrated better outcome for patients receiving the combination of GO and chemotherapy compared to chemotherapy alone [18]. Other studies have explored the combination of GO and other chemotherapy regimens in AML patients, such as cytarabine and mitoxantrone [19] and high-dose cytarabine, mitoxantrone, and all-trans retinoic acid [20]. Additionally, ongoing research is exploring the association of GO, mitoxantrone and etoposide (NCT03839446) and a liposomal cytarabine-daunorubicin (NCT05558124) for the same patient population.

BV is an anti-CD30 mAb conjugated through a protease-cleavable linker to the anti-mitotic cytotoxic agent monomethyl auristatin-E (MMAE) [21]. Based on its demonstrated clinical efficacy and its approval for treating patients with Hodgkin lymphoma (HL) and anaplastic large cell lymphoma [7–9], BV was further investigated in combination with other treatments. In a phase I trial involving treatment-naive HL patients, BV was assessed in combination with the standard ABVD (doxorubicin-bleomycin-vinblastine-dacarbazine) regimen or the modified AVD (ABVD without bleomycin) regimen [22]. Results showed a comparable rate of complete response (CR) but a significantly higher rate of G3 AEs, in particular pulmonary toxicities, in the ABVD arm. Based on these results, it was concluded that BV should not be used in bleomycin-containing regimens like ABVD [22]. The phase III ECHELON-1 study compared BV plus AVD to the standard ABVD regimen in patients with previously untreated stage III or IV HL. The experimental arm resulted in improved progression-free survival (PFS) and OS rates compared to the ABVD group [23, 24], with a manageable safety profile. Based on these results, in March 2018 the FDA approved the combination of BV with AVD for the treatment of previously untreated stage III/IV HL [25]. The superiority of BV plus chemotherapy, compared to chemotherapy alone, was demonstrated also in patients with previously untreated peripheral T-cell lymphoma (PTCL). In phase III ECHELON-2 trial, the standard CHOP (cyclophosphamide-doxorubicin-vincristine-prednisone) regimen was compared to the experimental arm of BV with CHP (a modified CHOP with the omission of vincristine due to overlapping neurotoxicity with BV), showing an improvement in both PFS and OS in the experimental arm, with a similar rate of G3 or higher AEs [26, 27]. This combination has been approved by the FDA in November 2018. In November 2022, a significant advancement in treatment emerged when the FDA approved a third combination involving brentuximab with chemotherapy. This approval represents a notable addition to the available therapeutic options for pediatric patients aged 2 years and older with previously untreated high-risk classical HL (cHL). The phase III study AHOD1331 demonstrated superior outcomes with the combination of BV alongside doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide in comparison to the standard ABVE-PC (doxorubicin-bleomycin-vincristine-etoposide-prednisone-cyclophosphamide) arm [28]. Numerous other trials are currently ongoing, exploring combinations with different chemotherapeutic regimens in hematologic malignancies A large phase III trial including 1,500 patients has compared the remodeled combination regimen BrECADD (BV, added to etoposide, cyclophosphamide, doxorubicin, dacarbazine, dexamethasone) versus the escalated BEACOPP (bleomycin-etoposide-doxorubicin-cyclophosphamide-vincristine-procarbazine-prednisone) regimen in patients with newly diagnosed advanced risk HL. Preliminary results showed no inferiority of the new regimen [29].

PV consists of an anti-CD79b mAb conjugated to MMAE through a cleavable linker [10]. PV, which was not approved as a single agent, in June 2019 received FDA approval for the treatment of patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) in combination with bendamustine-rituximab (BR) based on the results of a phase Ib/II trial that compared its efficacy and safety to bendamustine and rituximab [30]. Among other combinations with chemotherapy in different lymphoma subtypes, the most significant has been the phase III POLARIX trial that compared the combination with rituximab-CHP (R-CHP) to the standard rituximab-CHOP (R-CHOP) regimen in patients with untreated DLBCL. The experimental arm resulted in PFS benefits with similar OS rates [31]. This study led to the FDA approval of the combination PV-R-CHP in April 2023 for the treatment of untreated DLBCL, not otherwise specified (NOS), or high-grade B-cell lymphoma (HGBL).

Inotuzumab ozogamicin (INO), an anti-CD22 antibody conjugated to a calicheamicin payload via a cleavable linker [32], received FDA approval for use as a single agent in patients with R/R B-cell precursor acute lymphoblastic leukemia (ALL), based on the phase III IN-NOVATE trial [32]. A single-arm phase II trial investigated the efficacy of INO with mini-hyper CVD (cyclophosphamide-vincristine-methotrexate-cytarabine), with or without blinatumomab, in patients with B-cell ALL. It showed promising efficacy in terms of OS and even more favorable survival outcomes in the blinatumomab arm [33]. In the subgroup of older patients (≥ 60 years) with Philadelphia chromosome-negative B-cell ALL, more than 70% of the patients experienced G3–4 hematologic toxicity. Consequently, there is a need to further adjust and refine the combination regimen to enhance tolerability [34]. Other studies evaluated the efficacy and safety of INO in combination with various chemotherapy agents.

Trastuzumab emtansine (T-DM1) is an ADC that combines the human epidermal growth factor receptor 2 (HER2)-targeting humanized mAb trastuzumab with a maytansinoid toxin-DM1, through a non-cleavable linker [35]. It became the first ADC approved for the treatment of a solid malignancy, based on the phase III EMILIA trial which included patients with advanced breast cancer (BC) and resulted in a benefit in PFS and OS compared to lapatinib plus capecitabine [36, 37]. Following the results of the KATHERINE study, T-DM1 was also approved for patients with HER2-positive BC with residual disease after neoadjuvant therapy [38] and has been evaluated in other HER2-positive solid tumors [39, 40]. Combination therapies of T-DM1 with chemotherapy regimens (such as docetaxel and capecitabine) did not result in any improvements and were associated with increased toxicity [41, 42]. The phase II TRAXHER2 trial evaluated the efficacy and safety of T-DM1 in combination with capecitabine compared to T-DM1 alone in patients with metastatic BC (mBC). Patients in the combination arm experienced a higher rate of G3–4 AEs, without any significant benefit in clinical outcomes [41]. An increased rate of AEs resulting from overlapping toxicities was also demonstrated in two phase Ib/IIa studies that evaluated T-DM1 in combination with docetaxel and paclitaxel, with or without pertuzumab, in patients with mBC or locally advanced BC (LABC). While the combination showed significant clinical activity, its clinical use is limited due to the occurrence of AEs, leading to frequent dose reductions and interruptions [42, 43]. Therefore, there is a need to seek a different partner that could be safely combined with T-DM1. A potential combination with promising preclinical data could involve gemcitabine, which has been shown to upregulate the expression of HER2 in pancreatic ductal adenocarcinoma cells and BC cells [44, 45]. Presently, no ongoing clinical trials are evaluating this combination.

Trastuzumab deruxtecan (T-DXd) is an ADC consisting of an anti-HER2 mAb and a topoisomerase I inhibitor, the exatecan derivative DXd [46]. T-DXd was approved by the FDA for the treatment of HER2-positive and HER2-low mBC patients [47, 48] and HER2-positive gastric adenocarcinomas [49]. Additionally, the FDA has granted accelerated approval for T-DXd in the treatment of metastatic HER2-mutant non-small cell lung cancer (NSCLC) [50] and breakthrough therapy designations for treating patients with HER2-positive metastatic colorectal cancer (mCRC) and advanced HER2-positive solid tumors [51, 52]. T-DXd combinations are currently being investigated in ongoing clinical trials. The phase I/IIb Destiny-Breast07 trial is exploring various regimens, including combinations of T-DXd with paclitaxel for patients with HER2-positive mBC [53]. Additionally, another phase Ib study, Destiny-Breast08, will assess five different regimens, incorporating combinations of T-DXd with capecitabine, anastrozole, and fulvestrant in HER2-low mBC patients [54]. The investigation of treatment combinations involving T-DXd and chemotherapy extends beyond BC. In advanced HER2-positive gastric cancer, the phase Ib/II Destiny-Gastric03 trial is currently assessing T-DXd in combination with cytotoxic chemotherapy agents [5-fluorouracil (5-FU), capecitabine, oxaliplatin] and/or immunotherapy agents [55].

Mirvetuximab soravtansine (MIRV) is an ADC consisting of a humanized folate receptor alpha (FRα)-targeting mAb connected to the maytansinoid DM4, which induced mitotic arrest by suppressing microtubule dynamics [56]. Based on the results of the phase III SORAYA trial, the FDA granted MIRV priority review and subsequently accelerated approval in November 2022 for patients with platinum-resistant epithelial ovarian cancer expressing FRα [57]. MIRV has been studied in a phase Ib trial in platinum-sensitive, relapsed ovarian cancer patients in combination with carboplatin. The combination demonstrated clinical activity and a manageable safety profile [58].

Anetumab ravtansine (AR), an ADC composed of a fully human IgG1 anti-mesothelin mAb linked to the tubulin inhibitor DM4 via a cleavable linker, has demonstrated high cytotoxic activity in preclinical studies against mesothelin-expressing tumors such as mesothelioma, pancreatic cancer, NSCLC, and ovarian cancer [59]. Encouraging clinical activity was demonstrated in patients with advanced or metastatic solid tumors, particularly in mesothelioma patients [60]. Results from a phase Ib trial showed that the combination with pegylated-liposomal doxorubicin exhibited clinical activity and tolerability in patients with platinum-resistant ovarian cancer [61].

Depatuxizumab mafodotin (Depatux-M) is an ADC that targets the epidermal growth factor receptor (EGFR). It consists of the humanized recombinant mAb ABT-806, which is linked via a non-cleavable linker to the anti-microtubule agent monomethyl auristatin-F (MMAF) [62]. In the phase II trial INTELLANCE 2, the combination of Depatux-M and temozolomide (TMZ) was investigated in patients with recurrent EGFR-amplified glioblastoma. This study compared Depatux-M alone or in combination with TMZ versus lomustine or TMZ [63]. The combination arm showed improved OS compared to the control arm, suggesting a potential clinical benefit. The most common AE in the Depatux-M arms was reversible corneal epitheliopathy G3–4 [63]. A multicenter study conducted by the Italian Association of Neuro-Oncology further investigated this combination treatment in patients with recurrent glioblastoma and reported similar results. However, larger prospective studies would be necessary to confirm its efficacy and further explore its safety [64]. There are currently no ongoing studies.

Lorvotuzumab mertansine (LM) is a humanized anti-CD56 mAb linked via a cleavable linker to the maytansinoid DM1 [65]. It was evaluated in a phase I/II trial in combination with carboplatin and etoposide, in comparison to carboplatin and etoposide alone. This study involved patients with untreated extensive-stage small-cell lung cancer but yielded disappointing results both in terms of safety and efficacy [66]. The drug is no longer being developed, there are no ongoing studies with LM.

EV is an ADC directed against Nectin-4 and comprises a fully human mAb linked to MMAE [6]. It demonstrated survival benefits as monotherapy in pretreated patients with la/mUC [6] and received FDA approval in December 2023 in combination with pembrolizumab [5]. The effectiveness of the combination relies on EV’s ability to trigger immunogenic cell death and boost the infiltration of T-cells. Pembrolizumab further enhances the anti-tumor immune response, complementing EV’s actions [7]. The approval was based on the results of the EV-302/KN-A39 trial which demonstrated significant improvements in PFS and OS for patients with la/mUC treated with EV and pembrolizumab compared to platinum-based chemotherapy, confirming EV with pembrolizumab as the new standard of care for first-line la/mUC [5]. Further expanding the clinical exploration of EV combinations, the VOLGA trial (NCT04960709) assesses its combination with durvalumab and tremelimumab in neoadjuvant and adjuvant settings in patients with muscle-invasive BC (MIBC). This trial targets a patient population ineligible for cisplatin-based chemotherapy, addressing a significant unmet need in MIBC management. The rationale relies on using EV’s capability to induce immunogenic cell death in conjunction with the immune-modulating effects of two ICIs. This aims to improve disease control before surgery and delay the recurrence [8].

The combination of BV and ICIs has been a focus of several clinical trials. The phase I/II trial, CheckMate 436, evaluated the combination of BV and nivolumab in patients with R/R primary mediastinal B-cell lymphoma (PMBL). This trial showed significant anti-tumor activity and a manageable safety profile, emphasizing the efficacy and safety of BV with nivolumab [68]. Furthermore, BV was also examined in another phase I/II study involving patients with R/R HL in combination with ipilimumab, nivolumab, or both. These combinations demonstrated high activity and maintained generally favorable safety profiles, with follow-up reports indicating benefits in PFS [9, 69, 70]. Currently, ongoing phase II and phase III trials (NCT04561206, NCT03138499) aim to further assess the combination of nivolumab with BV. Additionally, a small cohort study involving BV and pembrolizumab was conducted as a single-center retrospective analysis on 10 patients with R/R HL. The study revealed impressive results in objective response rate (ORR) and complete metabolic response rate, along with a rapid median time to best response [71]. An ongoing phase II clinical trial (NCT04609566) is set to evaluate the efficacy and safety of this combination in patients with metastatic solid tumors after progression on prior programmed cell death 1 (PD-1) inhibitors [72]. Other studies are also underway, assessing the combination of BV and pembrolizumab in R/R HL, R/R T-cell lymphoma, and recurrent PTCL (NCT05180097, NCT05313243, NCT04795869).

Based on evidence suggesting that T-DM1 could elicit antitumor immunity and render the tumor cells sensitive to ICIs [73], the drug has been evaluated in combination with atezolizumab and pembrolizumab in various clinical trials. The phase 2 KATE2 trial evaluated T-DM1 with atezolizumab in patients with previously treated HER2-positive advanced BC. Although it did not show a significant improvement in PFS for the overall population, subgroup analysis indicated a PFS advantage for patients with programmed cell death ligand 1 (PD-L1) positive tumors [74]. These findings have led to the initiation of the phase III KATE3 trial (NCT04740918), focusing on patients with HER2-positive and PD-L1-positive LABC/mBC [75]. Furthermore, a phase Ib trial investigated atezolizumab with T-DM1 in HER2-positive early BC (eBC), LABC, or mBC, showing an acceptable safety profile, along with an enhanced adaptive immune response in eBC tumors compared to those with mBC [76]. In another phase I study, investigating the combination of T-DM1 and pembrolizumab in patients with HER2-positive mBC, the regimen exhibited clinical activity and was well tolerated. However, biomarker analyses were constrained due to the small sample size of the cohort, highlighting the need for larger studies to determine predictive markers of response [77, 78].

Following the results of the phase II DESTINY-Breast01 and phase 3 DESTINY-Breast04 trials in BC patients, along with data from preclinical models [79] new combination strategies are being investigated, incorporating T-DXd and ICIs in HER2-expressing tumors. A phase Ib study assessed T-DXd in combination with nivolumab for HER2-expressing advanced breast or urothelial cancers. This study reported promising results, with a disease control rate (DCR) of 90.6% in HER2-positive patients, and 75% in those with HER2-low BC, an acceptable safety profile, and a benefit in PFS [80]. The phase Ib/II BEGONIA trial delved deeper into T-DXd, this time combining it with durvalumab for untreated HER2-low expressing triple-negative BC (TNBC). Preliminary results were impressive, demonstrating a 100% ORR. Further data is anticipated to elucidate the impact of PD-L1 expression on these outcomes [81]. Additionally, the combination of T-DXd with pembrolizumab is currently under investigation in an ongoing phase Ib trial, targeting patients with HER2-expressing advanced/mBC or NSCLC [82]. Another study in the pipeline is the phase Ib/II trial in gastric cancer, DESTINY-Gastric03 (NCT04379596). In addition, ongoing clinical trials are evaluating the safety and antitumor activity of T-DXd, durvalumab, and pertuzumab for HER2-positive mBC (NCT04538742, NCT04784715).

Sacituzumab govitecan (SG) is composed of the mAb anti-Trop2 linked to the active metabolite of irinotecan, SN-38 [83, 84]. The drug is FDA-approved as a single-agent treatment for breast and urothelial cancer. The TROPHY-U-01 Cohort 3 evaluated the combination of SG with pembrolizumab in patients with metastatic urothelial cancer who progressed after platinum-based regimens, showing an encouraging ORR and clinical benefit rate, as well as a manageable safety profile [85]. In addition to this, ongoing research is evaluating the activity of SG in various other clinical contexts and at earlier stages of treatment. For instance, the EVOKE-02 phase II trial is assessing SG in combination with chemotherapy and ICIs as a first-line treatment for patients with non-oncogene addicted NSCLC (NCT05186974). Similarly, a phase I/II study explored the potential of SG when combined with ipilimumab and nivolumab as a first-line therapy for cisplatin-ineligible advanced urothelial carcinoma (UC), demonstrating antitumor activity for this patient population representing an unmet medical need [86].

Based on the findings from the innovaTV 204 trial, the FDA granted accelerated approval to tisotumab vedotin (TV), which targets tissue factors and is linked to MMAE, for patients with recurrent or metastatic cervical cancer (r/mCC) [87]. The dose expansion arms of the phase Ib/II trial innovaTV 205/GOG-3024/ENGOT-cx8, evaluated TV with carboplatin as first-line treatment or with pembrolizumab as first or second-/third-line treatment in patients with r/mCC. The study met its primary endpoint demonstrating promising anti-tumor activity and acceptable safety profiles [88].

Preclinical data suggest that MIRV may activate monocytes and upregulate immunogenic cell death markers in ovarian cancer cells [89]. Building on these findings, the phase Ib/II FORWARD II study delved further into the potential of MIRV, in combination with pembrolizumab and bevacizumab, focusing on patients with platinum-resistant ovarian cancer. The combination of MIRV with pembrolizumab was generally well tolerated, with few G3 AEs [90]. Complementing these findings, additional research is being conducted in patients with endometrial cancer (NCT03835819).

Ladiratuzumab vedotin (LV) is a novel ADC that combines anti-LIV-1 mAb with MMAE via a protease-cleavable linker [91]. LIV-1 is a transmembrane protein with zinc transporter and metalloproteinase activity, primarily expressed in melanoma, breast, and prostate cancers, while having limited expression in normal tissues [91]. Early-phase studies have shown promising antitumor activity, particularly in heavily treated metastatic TNBC [92]. The combination of LV with pembrolizumab has been evaluated in the first-line therapy of patients with TNBC demonstrating a good tolerability profile and clinical activity [93]. Ongoing research is currently exploring LV in combination with atezolizumab for locally advanced and metastatic TNBC (NCT03424005).

Disitamab vedotin (RC48-ADC) is an anti-HER2 ADC composed of a novel anti-HER2 mAb (hertuzumab), coupled with MMAE by a cleavable linker [94]. Promising data have been observed in both HER2-positive and HER2-negative populations with la/mUC [95]. In a phase Ib/II trial RC48-ADC was studied in combination with toripalimab, an anti-PD-1 antibody known for its clinical activity in UC [96, 97]. The combination showed an ORR of 75% in patients with la/mUC. The ORR was even higher for patients who were HER2 positive and PD-L1 positive. However, antitumor activity was also observed in patients with HER2 2+, 1+, 0, and in those with a PD-L1 level below 1 [96]. The same combination was explored in patients with HER2-expressing advanced gastric or gastroesophageal junction with similar, positive, findings [98].

A study with AR combined with pembrolizumab in pleural mesothelioma patients showed a higher stable disease rate and median PFS than pembrolizumab alone, although these weren’t statistically significant, possibly due to a smaller sample size [99]. Furthermore, a phase Ib study in pancreatic cancer showed a good DCR and tolerability for AR combined with immunotherapy or chemotherapy [100].

Belantamab mafodotin (BM) is a novel ADC developed using a B cell maturation antigen (BCMA)-targeted mAb. BCMA, a part of the tumor necrosis factor (TNF) receptor superfamily, is expressed on both normal and malignant plasma cells, as well as late B-cells [101, 102]. The antibody component is linked to MMAF through a protease-resistant linker [103]. BM’s efficacy in treating R/R multiple myeloma (MM) has been evaluated in several clinical studies, demonstrating benefits in PFS, OS, and a manageable safety profile [104]. These results initially led to its FDA approval for monotherapy in R/R MM patients who had undergone four or more lines of therapy. However, in November 2022, this approval was withdrawn following the outcomes of the DREAMM-III study, which did not meet the FDA’s accelerated approval guidelines (NCT04162210). In experimental studies, combining BM with an OX40 agonist has been shown to enhance anti-cancer effects, resulting in increased activity of T cells and dendritic cells within tumors [105]. Clinical trials such as the DREAMM-5 study are exploring this approach, investigating the combination of BM with various immune therapies, including anti-PD-1 and anti-inducible T-cell co-stimulator (ICOS) antibodies, and a γ-secretase inhibitor [106]. A preliminary analysis of 23 patients in this trial indicated that BM combined with anti-ICOS displayed encouraging clinical activity and a manageable safety profile through dose modifications [106]. Additionally, the DREAMM-4 study, which investigated the combination of BM and pembrolizumab, concluded that this combination yielded a favorable ORR and had a safety profile comparable to BM monotherapy [107].

Datopotamab deruxtecan (Dato-DXd) is a novel ADC comprising a humanized anti-TROP2 IgG1 mAb linked to a potent DNA topoisomerase I inhibitor via a cleavable linker [108]. Early phase trials from the TROPION series evaluated the efficacy and safety of Dato-DXd in multiple tumors at different stages, revealing promising clinical activity in both NSCLC and TNBC [109]. Encouraging results from early trials have led to further exploration of Dato-DXd in combination with ICIs. For instance, The TROPION-Lung02 trial investigated Dato-DXd with pembrolizumab ± chemotherapy in metastatic NSCLC patients, reporting an acceptable safety profile and clinical activity. This has led to ongoing studies like TROPION-Lung07 and TROPION-Lung08, which aim to explore Dato-DXd in combination with ICIs, with or without chemotherapy, potentially as first-line treatments [110]. In metastatic TNBC, the phase Ib/II BEGONIA trial evaluated the combination of Dato-DXd and durvalumab, demonstrating a highly encouraging ORR of 79% regardless of PD-L1 expression level, with a safety profile consistent with the known profiles of both agents [111]. Additionally, other studies are assessing the same combination in different stages of BC, ranging from perioperative treatment to therapy of advanced disease (NCT06112379, NCT05629585, NCT06103864). Finally, TROPION-PanTumor03 is set to evaluate Dato-DXd both as monotherapy and in combination with other antitumor agents across various solid cancer types (NCT05489211).

The ECHELON-3 study evaluated a novel combination therapy of BV, lenalidomide, and rituximab for R/R DLBCL in patients ineligible for hematopoietic stem cell transplantation (HSCT) or CAR-T therapy. The study involved 10 patients, revealing a 70% ORR with a manageable safety profile, indicating the promising efficacy of this triplet regimen in R/R DLBCL, with the randomized study phase currently ongoing [112].

PV is currently being evaluated in combination with rituximab and bispecific antibodies [113–116]. The phase Ib/II study combining PV with mosunetuzumab, a bispecific antibody targeting CD20 and CD3, in relapsed/refractory B-cell non-HL demonstrated promising safety and efficacy, especially for elderly patients with limited treatment options [116]. Additionally, a phase II study evaluating rituximab with either PV or pinatuzumab vedotin in a similar patient population showed efficacy, with a preference for rituximab-PV due to longer response duration and a better safety profile [115]. A phase Ib/II study evaluated PV combined with obinutuzumab and lenalidomide in patients with heavily pre-treated refractory follicular lymphoma [69]. Additionally, PV was studied in combination with bcl-2 inhibitor venetoclax, and as part of a triplet therapy with both venetoclax and rituximab [117, 118]. The phase Ib study investigated the combination of PV with venetoclax and rituximab in R/R DLBCL, showing promising activity and a favorable safety profile [117]. The same combination was explored in the patients with R/R follicular lymphoma, replacing rituximab with obinutuzumab, also yielding encouraging results [119, 120].

The combination of INO and rituximab was explored in a phase I/II trial in patients with DLBCL of follicular lymphoma, showing high antitumor activity and a manageable safety profile [121]. A phase III trial failed to demonstrate the superiority of the experimental arm compared to the standard [122]. A phase I trial evaluated the combination of INO with temsirolimus in patients with R/R CD22-positive B-cell non-HL. Due to the high rate of toxicities at therapeutic doses, it was concluded that further development of this drug combination was not feasible, despite demonstrating clinical activity [123]. Another early-phase trial explored the combination of INO with bosutinib for R/R Philadelphia chromosome-positive ALL or the lymphoid blast phase of chronic myeloid leukemia, demonstrating clinical activity in terms of ORR and a good tolerability profile [124].

Loncastuximab tesirine (LT) is an anti-CD19 ADC, linked to a pyrrolobenzodiazepine dimer cytotoxin, SG3199 [125]. The results of the LOTIS-2 trial led to the FDA’s approval of LT as a single agent for treating patients with R/R large B-cell lymphoma (DLBCL, transformed DLBCL, and HGBL) [125]. Results from a phase I/II study exploring the combination of LT and ibrutinib in patients with DLBCL and mantle cell lymphoma demonstrated antitumor activity and manageable toxicity [126]. Current evaluations include its combination with rituximab in R/R follicular lymphoma and various DLBCL settings (NCT04998669, NCT05144009, NCT04384484).

In the phase III trials KAITLIN, MARIANNE, and KRISTINE, the combination of T-DM1 with pertuzumab, whether used in early or advanced HER2-positive BC, did not show improved clinical activity compared to the standard of care [127–129]. The phase II trial TEAL explored the combination of T-DM1, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive BC in the neoadjuvant setting. The experimental arm was associated with higher activity compared to the standard arm [130]. The phase III study HER2CLIMB-02 investigated the combination of T-DM1 and tucatinib in advanced HER2-positive BC, presenting results at the San Antonio Breast Cancer Symposium 2023. This combination significantly improved PFS compared to the control arm, also showing responses in patients with brain metastasis. However, it was associated with a higher rate of AEs, although generally manageable [131].

Neratinib, an irreversible panHER inhibitor, has the potential to overcome trastuzumab resistance by inhibiting downstream pathways [132]. In a small cohort of patients with HER2-positive mBC, the combination yielded an ORR of 63% with an acceptable safety profile [133]. Other studies are exploring the combination of T-DM1 with ribociclib or alpelisib in patients with HER2-positive mBC demonstrating good tolerability and promising activity [134, 135].

The combination of T-DM1 and pertuzumab was explored in the HERACLES-B trial for patients with HER2-positive advanced colorectal cancer, but the trial failed to meet its primary endpoint (ORR ≥ 30%) [136]. Another study investigating the combination of osimertinib plus T-DM1 in patients with advanced EGFR mutant and HER2-positive NSCLC exhibited limited efficacy [137].

A phase I trial, evaluated EV with SG in mUC demonstrating significant clinical activity with the evidence of complete responses [138]. EV with erdafitinib is under evaluation in a phase I study involving patients with metastatic urothelial cancer (NCT04963153). Another trial is investigating EV in combination with cabozantinib in subjects with locally advanced or metastatic urothelial cancer (NCT04878029).

Preclinical evidence suggests a potential benefit of combining SG with polyadenosine-diphosphate-ribose polymerase (PARP) inhibitors in models of TNBC [139]. The combination of SG and rucaparib has been evaluated in the phase Ib SEASTAR study in patients with advanced TNBC, advanced platinum-resistant ovarian cancer, and solid tumors with mutations in homologous recombination repair genes. Despite signs of activity, further investigation is required due to safety concerns, particularly the high rate of myelosuppression [140]. Several studies are investigating SG plus talazoparib in metastatic TNBC (mTNBC) [141], and berzosertib [a potent and selective small-molecule Rad3-related kinase (ATR) inhibitor] in SCLC [142] and homologous recombination-deficient neoplasms who are progressive to PARP inhibitors (NCT04826341). Preliminary results from the phase I trial investigating SG and berzosertib have recently been published: objective responses were observed in 3 of 12 evaluable patients, and the ongoing phase II expansion cohorts are currently evaluating the efficacy [143].

The phase Ib/II FORWARD II evaluated MIRV, in combination with pembrolizumab and bevacizumab in patients with platinum-resistant ovarian cancer. The combination with bevacizumab is supported by evidence indicating enhanced antitumor activity, attributed to bevacizumab’s capacity to facilitate tumor penetration and exposure to the ADC [144]. It demonstrated notable effectiveness, yielding improved responses in patients regardless of their platinum sensitivity status. The combination was particularly effective in patients with high FRα expression tumors and in those who had not previously received bevacizumab [145]. These findings suggest that MIRV, in combination with bevacizumab, could represent a promising alternative to standard therapies for ovarian cancer, even for patients who have received prior treatments. A phase 1 study is currently assessing the combination of MIRV with rucaparib in patients with recurrent endometrial, ovarian, fallopian tube, or primary peritoneal cancer (NCT03552471). Another phase Ib trial is evaluating MIRV alongside SL-172154, a fusion protein consisting of human signal-regulatory protein alpha (SIRPα) and CD40L linked via a human Fc, in patients with platinum-resistant ovarian cancer (NCT05483933).

The combination of BM with lenalidomide and dexamethasone has been evaluated in two clinical trials: the BelaRd study for naive MM patients and the DREAMM-6 study for R/R MM patients. Both studies indicated a rate of G3 AEs up to 94% across various dose levels. However, these AEs were generally manageable with dose modifications, and there were notable signs of clinical activity [146, 147]. The phase III trial DREAMM-8 is currently exploring BV with dexamethasone and pomalidomide in R/R MM (NCT04484623). Other ongoing combination regimens include BM with lenalidomide and daratumumab in relapsed or newly diagnosed MM (NCT04892264), BM plus bortezomib and dexamethasone (NCT04246047), among others.

A phase II trial assessing the combination of AR with bevacizumab, compared to paclitaxel with bevacizumab in patients with platinum R/R ovarian cancer, reported poorer outcomes with the AR and bevacizumab combination, leading to the study’s termination [148].

Patritumab deruxtecan consists of an anti-HER3 mAb attached to a topoisomerase I inhibitor via a cleavable linker [149]. Preclinical findings showed that the therapy with EGFR-TKI increases HER3 expression, thus improving the anticancer activity of patritumab deruxtecan [150] and providing a rationale for an ongoing study which is evaluating patritumab deruxtecan plus osimertinib in patients with advanced EGFR-mutated NSCLC (NCT04676477).

Coltuximab ravtansine (SAR3419) is an ADC consisting of an anti-CD19 mAb conjugated with a cleavable linker to DM4 [151]. It has shown promising activity as a single agent in a phase II study in R/R DLBCL with benefits in PFS and OS [152]. A phase II trial was conducted in combination with rituximab in subjects with R/R DLBCL. The primary goal of ORR was not met, and there are no ongoing studies at the moment exploring this drug [153].

Moxetumomab pasudotox (MOXE) is an ADC composed of a mAb anti-CD22 linked to pseudomonas exotoxin A (PE38). The drug received FDA approval in 2018 for the treatment of patients with pretreated hairy-cell leukemia (HCL) [154]. In July 2023 the company AstraZeneca decided to remove the drug from the market due to lack of use and the availability of other treatment options [155].